Metraipolis › archive › dc_f460dc514ca0

Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties — Europe PMC PMID:42761341

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42761341
DOI
10.37349/etat.2026.1002400
License (as archived)
solo-consultazione
Archived
2026-10-15T17:41:51.411Z
SHA-256 of the archived text
e3391230debc85eda563a16e4cad0dfb28ef690d3cc886c1080685ddb4e440bd
Stable URL of this page
https://metraipolis.com/documento/dc_f460dc514ca0

How to cite

Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties — Europe PMC PMID:42761341 — Europe PMC (en), https://europepmc.org/article/MED/42761341 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f460dc514ca0 (Metraipolis archive dc_f460dc514ca0, sha256 e3391230debc85eda563a16e4cad0dfb28ef690d3cc886c1080685ddb4e440bd)
BibTeX
@misc{dcf460dc514ca0,
  title = {Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties — Europe PMC PMID:42761341},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42761341},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f460dc514ca0; sha256 e3391230debc85eda563a16e4cad0dfb28ef690d3cc886c1080685ddb4e440bd},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42761341. Agents can read the archived copy with the MCP tool read_document.